Citeline Podcasts

Interview with Joe Jimenez, EFPIA President and Novartis CEO on Reputation.

On this week's podcast, Ferdous Al-Faruque discusses next-generation sequencing developments and progress by one company in the liquid biopsy space, while Elizabeth Orr previews an upcoming FDA patient-preference workshop and talks about a guidance document from the US agency on adaptive clinical trials. Please listen to our podcast.

On this week's podcast, Ferdous Al-Faruque discusses next-generation sequencing developments and progress by one company in the liquid biopsy space, while Elizabeth Orr previews an upcoming FDA patient-preference workshop and talks about a guidance document from the US agency on adaptive clinical trials. Please listen to our podcast.

On this week's podcast, Ferdous Al-Faruque discusses next-generation sequencing developments and progress by one company in the liquid biopsy space, while Elizabeth Orr previews an upcoming FDA patient-preference workshop and talks about a guidance document from the US agency on adaptive clinical trials. Please listen to our podcast.

This month Guardant Health became the first company to get its liquid biopsy test, the Guardant 360, covered by a health insurance company. CEO Helmy Eltoukhy, spoke to MedTech Insight about the mile-marker and said other laboratory test developers need to get on FDA's LDT regulatory bandwagon for everyone's best interest.

This month Guardant Health became the first company to get its liquid biopsy test, the Guardant 360, covered by a health insurance company. CEO Helmy Eltoukhy, spoke to MedTech Insight about the mile-marker and said other laboratory test developers need to get on FDA's LDT regulatory bandwagon for everyone's best interest.

This month Guardant Health became the first company to get its liquid biopsy test, the Guardant 360, covered by a health insurance company. CEO Helmy Eltoukhy, spoke to MedTech Insight about the mile-marker and said other laboratory test developers need to get on FDA's LDT regulatory bandwagon for everyone's best interest.

Elizabeth Mansfield, FDA’s top official on personalized medicine, spoke to MedTech Insight about the agency’s thoughts behind two recently released next-generation sequencing draft guidances and where it plans to go next on the topic.

Elizabeth Mansfield, FDA’s top official on personalized medicine, spoke to MedTech Insight about the agency’s thoughts behind two recently released next-generation sequencing draft guidances and where it plans to go next on the topic.

Elizabeth Mansfield, FDA’s top official on personalized medicine, spoke to MedTech Insight about the agency’s thoughts behind two recently released next-generation sequencing draft guidances and where it plans to go next on the topic.